The takeaway
Abcellera Biologics Inc shows a pronounced seasonal pattern over 6 years of data — strongest in July (+6.2%) and softest in February (−15.3%).
Right now
In July, the stock has risen 60% of years, averaging +6.2%, about +4.0 pts better than the S&P 500.
The full picture
Abcellera Biologics Inc's most dependable month has been July, higher in 3 of 5 years; February has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | — | — | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in June (+10.1 pts); it has trailed the market most in February (−15.0 pts).
“vs S&P” is Abcellera Biologics Inc’s average for a month minus the S&P 500’s average for that same month — isolating Abcellera Biologics Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, July has closed higher 60% of the time versus 60% across the last 6 years — the pattern is holding.
Figures are the typical (median) July return and how often it rose — the last 5 years versus the last 6(the heatmap’s default window). This verdict stays anchored to that 6-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
There's a real but measured seasonal tilt here, toward July — the firmest corner of the calendar, higher in 3 of 5 Julys.
The strength looks broad-based rather than freakish: its average (+6.2%) and median (+17.3%) sit close together, so no single blow-out year is flattering the figure. That reliability comes with real swings, mind — even July ranges by 19.6% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — July has outpaced the S&P 500 by +4.0 points on average. Some of that is a strong month market-wide, mind — July rises for about 61% of stocks — so the tendency is real if not unique.
It doesn't stand entirely alone — January, May, and September have leaned firm as well, if less emphatically. At the other end of the calendar, February has been the soft spot — the weakest of 7 months that average a loss (−15.3%), and the edge isn't year-round — the stock has trailed the S&P 500 in February, April, and December. Its roughest month on record was a −36.4% January in 2022 — a reminder of how hard even a seasonal name can fall.
Treat it as a tendency rather than a rule — seasonality describes the past, not a promise. With a short 6-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (July), its worst (February), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2020 its best month (July, +6.2%) has run well ahead of its worst (February, −15.3%) — the heatmap above shows how steady that gap has been year to year.
July has been the strongest, averaging +6.2% and closing higher in 3 of 5 years since 2020.
It's the weakest, averaging −15.3% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade